AnGes/GenoLac's novel oral HPV vaccine shows early promise
This article was originally published in Scrip
Executive Summary
The Japanese bioventure AnGes MG has unveiled preliminary clinical results with a novel oral vectored vaccine against human papillomavirus (HPV) that it sees as sufficiently promising to warrant the product's continued development.